Vaptans Market
Number of pages: 100 | Report Format: PDF | Published date: April 21, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
|
Report Attribute |
Details |
|
Market Size Value in 2022 |
US$ 1.80 billion |
|
Revenue Forecast in 2031 |
US$ 2.72 billion |
|
CAGR |
4.7% |
|
Base Year for Estimation |
2022 |
|
Forecast Period |
2023 to 2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Category, Indication, Route of Administration, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global vaptans market was valued at US$ 1.80 billion in 2022 and is expected to register a revenue CAGR of 4.7% to reach US$ 2.72 billion by 2031.
Vaptans Market Fundamentals
Vaptans are a class of drugs used to treat various conditions related to fluid imbalance in the body. Vaptans are also known as selective vasopressin receptor antagonists, which block the effects of vasopressin, a hormone that regulates the body's water balance. Vaptans drugs are primarily used to treat hyponatremia, a condition in which the sodium level in the blood is too low. Various factors, such as heart failure, liver disease, or the use of certain medications, can cause hyponatremia. Vaptans work by increasing the excretion of water from the body, which in turn helps increase sodium concentration in the blood. Several vaptans are approved for use in various countries, including tolvaptan, conivaptan, and satavaptan. These drugs are typically administered orally or intravenously under medical supervision.
[547567]
Vaptans Market Dynamics
The growing prevalence of conditions that cause fluid imbalance, such as heart failure and liver disease, is a major driver of the vaptans market. As the number of patients with these conditions increases, so does the demand for vaptans. Advancements in drug development have also contributed to the revenue growth of the vaptans market. Developing new vaptans with better efficacy and fewer side effects has increased their adoption and use in clinical settings. Ongoing research and development of new vaptans may also contribute to market revenue growth. The regulatory environment for vaptans has been favorable, with several drugs receiving regulatory approval in various countries. As healthcare spending increases globally, patients and healthcare providers are more willing to use expensive drugs like vaptans to treat serious medical conditions. Healthcare providers and patients are increasingly aware of the importance of maintaining fluid balance in the body. This increased awareness has led to a more frequent diagnosis of conditions such as hyponatremia, a key indication for vaptans.
However, vaptans are generally expensive drugs, which can significantly restrain their adoption and use in clinical settings. Vaptans can have side effects like thirst, dry mouth, and nausea. In rare cases, vaptans can cause serious adverse events, such as liver damage. These side effects are restricting vaptans market revenue growth. Moreover, alternative treatments are available for conditions that vaptans treat, such as diuretics and fluid restriction. These alternative treatments are more cost-effective and have fewer side effects, hampering the revenue growth of the vaptans market.
Vaptans Market Ecosystem
The global vaptans market is analyzed from four perspectives: category, indication, route of administration, and region.
Vaptans Market by Categories
[754745]
Based on the categories, the global vaptans market is segmented into selective vaptans and nonselective vaptans. The selective vaptans segment is further sub-segmented into tolvaptan, lixivaptan, and others.
The nonselective vaptans segment accounted for a significant vaptans market revenue share in 2022. The nonselective vaptans, such as conivaptan, were among the first vaptans to receive regulatory approval and enter the market. This gave them a head start over the more recently developed selective vaptans regarding market share and awareness among healthcare providers. Nonselective vaptans have a broader range of indications than selective vaptans. For example, in hospitalized patients, conivaptan is approved for treating both hyponatremia and euvolemic and hypervolemic hypervolemic hyponatremia. This broad range of indications may have contributed to their dominance in the market. Nonselective vaptans are generally considered more potent and have a faster onset of action than selective vaptans. This may make them a more attractive treatment option for patients with severe fluid imbalances or use in acute care settings.
The selective vaptans segment accounted for a considerable revenue share of the vaptans market in 2022. Selective vaptans are designed to target a specific subtype of vasopressin receptor, which may reduce their potential for off-target effects and adverse events. This improved safety profile may make them a more attractive treatment option for patients and healthcare providers. Selective vaptans are generally associated with fewer side effects than nonselective vaptans. This may improve patient compliance and lead to greater adoption of these drugs in clinical settings. Selective vaptans have more targeted indications than nonselective vaptans. For example, tolvaptan is approved for treating hyponatremia in patients with heart failure and the syndrome of inappropriate antidiuretic hormone secretion (SIADH). This targeted indication may make them a more effective treatment option for specific patient populations. Selective vaptans are effective in clinical studies for treating hyponatremia and other fluid imbalances. Positive clinical data may increase healthcare providers' confidence in these drugs' efficacy and contribute to their market share.
Vaptans Market by Indication
Based on the indications, the global vaptans market is segmented into hyponatremia, autosomal dominant polycystic kidney disease (ADPKD), and others.
The hyponatremia segment dominated the vaptans market with the largest revenue share in 2022. Hyponatremia is a common electrolyte imbalance, particularly among hospitalized patients, and it can be a serious medical condition if left untreated. The high prevalence of hyponatremia has contributed to the dominance of this segment in the vaptans market. Before the development of vaptans, the treatment options for hyponatremia were limited to fluid restriction and diuretics. Vaptans represented a novel and effective treatment option for this condition, which may have contributed to their adoption and market dominance. The first vaptan to receive regulatory approval was conivaptan, which is approved for treating euvolemic and hypervolemic hyponatremia in hospitalized patients. Subsequently, selective vaptans such as tolvaptan and satavaptan were also approved for the treatment of hyponatremia. The approved indications for vaptans have largely been focused on treating hyponatremia, which has propelled the dominance of this segment in the market. Clinical studies have shown that vaptans are effective in the treatment of hyponatremia; this is also expected to propel the segmented growth.
The autosomal dominant polycystic kidney disease (ADPKD) segment accounted for a considerable vaptans market revenue share in 2022. The high prevalence of ADPKD is contributed to the demand for vaptans as a treatment option. It is characterized by the growth of multiple cysts in the kidneys, which can lead to kidney failure and the need for renal replacement therapy. According to the National Institute of Diabetes And Digestive and Kidney Diseases (NIDDK), ADPKD affects 1 in every 400 to 1,000 people worldwide. Before the development of vaptans, the treatment options for ADPKD were limited to supportive measures, such as blood pressure control and, eventually, renal replacement therapy. Vaptans represent a novel and effective treatment option for ADPKD, contributing to their adoption and market share. Tolvaptan is the only vaptan currently approved for treating ADPKD in multiple countries. Clinical trials have demonstrated the efficacy of tolvaptan in reducing the rate of kidney disease progression among ADPKD patients, which is boosting segmental revenue growth.
Vaptans Market by Route of Administration
Based on the route of administration, the global vaptans market is segmented into oral and intravenous.
The oral segment accounted for the prominent vaptans market revenue share in 2022. Oral vaptans are convenient to administer, as they can be taken orally without invasive procedures. Oral vaptans have demonstrated efficacy in treating hyponatremia and ADPKD, making them a popular treatment option. Oral vaptans are generally well-tolerated, with few reported adverse effects. This has contributed to their popularity as a treatment option for hyponatremia and ADPKD. Many vaptans, including the most commonly prescribed vaptan, tolvaptan, are available in oral formulations, making them easily accessible to patients and healthcare providers. Oral vaptans are typically less expensive than other routes of administration, such as intravenous or subcutaneous, making them a more affordable treatment option for patients and healthcare providers.
The intravenous segment accounted for a significant revenue share of the vaptans market. Intravenous vaptans can rapidly increase serum sodium levels, making them useful in emergencies such as severe hyponatremia. Intravenous vaptans have higher bioavailability than oral formulations, leading to more effective treatment in some cases. Healthcare professionals can administer intravenous vaptans in a controlled manner, ensuring accurate dosing and reducing the risk of medication errors. Intravenous vaptans have been approved for various indications, including hyponatremia associated with heart failure, liver cirrhosis, and syndrome of inappropriate antidiuretic hormone secretion.
Vaptans Market by Region
Based on region, the global vaptans market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
North America has the largest vaptans market size in terms of revenue generation. North America has a relatively high prevalence of hyponatremia, a condition that can be treated with vaptans. This has contributed to the revenue growth of the vaptans market in the region. According to the National Institute of Diabetes And Digestive and Kidney Diseases (NIDDK), polycystic kidney disease affects about 500,000 people in the U.S. The aging population in North America is at an increased risk of developing hyponatremia, heart failure, and other conditions that can be treated with vaptans. Developing new and innovative vaptans has driven revenue growth in vaptans market in North America. This includes the development of selective vaptans and novel formulations, such as long-acting vaptans. Favorable reimbursement policies in the region have made vaptans more affordable and accessible to patients, driving demand for these drugs. Moreover, There has been a growing awareness of the benefits of vaptans in treating hyponatremia and other conditions, leading to increased education among healthcare professionals and patients. This is also expected to fuel regional revenue growth.
Vaptans Competitive Landscape
The prominent players operating in the global vaptans market with the largest revenue share are:
Vaptans Strategic Developments
Vaptans are a class of drugs used to treat various conditions related to fluid imbalance in the body. Specifically, they are selective vasopressin receptor antagonists, which block the effects of vasopressin, a hormone that regulates the body's water balance.
The expected size of the global vaptans market in 2031 is US$ 2.72 billion.
Asia Pacific is a key growth region due to the surge in the demand for vaptans in China, Japan, and the Indian subcontinent.
The prominent players operating in the global vaptans market are Astellas Pharma, Inc., Otsuka Pharmaceutical Co., Ltd., Ascend Laboratories, LLC, Camber Pharmaceuticals, Inc., and Par Pharmaceutical, Inc.
The global vaptans market is expected to register a revenue CAGR of 4.7% during the forecast period.
*Insights on financial performance are subject to the availability of information in the public domain